Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Antiviral Res. 2014 Oct 5;0:1–7. doi: 10.1016/j.antiviral.2014.09.012

Figure 4. SVN treatment protects mice when begun before virus challenge.

Figure 4

Groups of 10 mice were injected s.c. every 6 hours, beginning 24 hr before virus challenge, to give a total daily dose of 10 (red square), 20 (green triangle) or 30 (purple triangle) mg/kg. The initial doses were given at −24, −18, −12 and −6 hr, then 1 hr after i.p. virus challenge, and continuing every 6 hr through day 9 (arrow). Control groups were infected and treated with PBS (blue circle), or were left uninfected (black circle) and given a total daily dose of 30 mg/kg of SVN (orange diamond). A. Percent survival. A log-rank test was performed to compare survival of treated and untreated, infected mice; (*) denotes statistical significance with a 95% CI and p = 0.0006, while (**) denotes p < 0.0001. B. Percent weight change relative to mean group weight on day −1. A two-way ANOVA was performed and no significant difference was found in the weight changes between treatment groups and the uninfected, PBS-treated control group.